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Introduction
Taxans, paclitaxel and docetaxel, are highly effective
chemioterapeuthics commonly used against breast
cancer. Docetaxel is a hemisyntetic taxan, which acts
on microtubules similarly to paclitaxel [1,2]. However,
it is more potent than paclitaxel both in in vitro and in
vivo conditions. Therefore, it can be used in lower
therapeutic dosages than paclitaxel [1,3]. It was proved
that docetaxel through Bcl-2 protein phosphorilization
had induced apoptosis of cancer cells in concentration
100 times lower than paclitaxel [4] and demonstrated
higher effectiveness [5,6]. An uptake and a retention of
docetaxel by cancer cells is better than paclitaxel [7].
The experiments conducted on many different cancers
proved higher cytotoxicity of docetaxel in comparison
to paclitaxel [8]. On the other hand, the resistance  of
breast cancer cells on decetaxel is observed and severe
side effects are observed when docetaxel is used for
long period and in high dosages [9].  Therefore, it seems
to be important to find out the substances which could
potentialize docetaxel anitcancer activity when it is used
in low concentration. Taxans have high activity against
breast cancer cells either as the single agent or in com-
bination with other anticancer compounds [10]. Among
many  substances, the vitamin A family has ability to
suppress growth and proliferation of breast cancer cells
[11,12]. Vitamin A metabolites acts throughout RAR
and RXR receptors belonging to group of steroid/thy-
roid receptors regulating genes expressions [13]. There-
fore, retinoids may express their anti-cancer activity by
means of the organ specific mechanisms [14]. It is
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belived that retinoids can suppress cancer growth by
inhibition of cells proliferation,  promotion of cells dif-
ferentiation as well as induction of apoptosis.  Taxans
and retinoids have similar point of action, which is Raf-
1. Retinoids potentialize the activation of Raf-1 induced
by taxans [15].  Susceptibility of MCF-7 breast cancer
cells on anticancer agents like taxans can be potential-
ized by preincubation with retinoic acid [16].
The aim of our study was to investigate the effect
of all-trans retinol, carotenoids (β-carotene, lycopene)
and retinoids (9-cis, 13-cis, and all-trans retinoic acid)
on the activity of docetaxel and to compare these
effects with the estradiol and tamoxifen actions on
human ER(+) MCF-7 breast cancer cell line.
Materials and methods 
Chemicals. Retinol (all-trans retinol, Sigma) β-carotene (β-
carotene, Sigma), lycopen (Lycopene, Sigma),  9-cis retinoic acid
(9-cis Retinoic acid, Sigma), 13-cis retinoic acid (Isotretinoin), all-
trans retinoic acid (Tretinoin), tamoxifen (Citrate Salt Tamoxifen),
17β-estradiol (1,3,5 [10]-estratriene-3, 17β-diol) and docetaxel
(Taxotere, ≥ 97% [HPLC]) were obtained from Sigma (St. Louis,
MO, USA). The following antibodies: PCNA - Proliferating Cell
Nuclear Antigen: monoclonal mouse antibody (clone PC 10) and
Ki 67: monoclonal mouse antibody  (clone Ki 67) were obtained
from Dako (Glostrup, Denmark).
Retinol, carotenoids and retinoids were diluted in ethyl alcohol
(lycopene in THF) and then in the culture medium, to final con-
centrations of 0.001 - 10 μM. Tamoxifen and 17β-estradiol were
added to the culture at a concentration of 10 and 0.001 μM, respec-
tively. Docetaxel was diluted in the culture medium to final con-
centrations of 0.00001, 0.0001, 0.001, 0.01, 0.1, 0.2, 0.5, 1.0 and
10.0 μM.
Culture of cell line MCF-7. The study was carried out on the hor-
mone sensitive cell line (ER+) MCF-7 of human breast cancer
(American Type Culture Collection, Rockville, MD) in DMEM
medium (Sigma, St. Louis, MO, USA) supplemented with 10%
FBS (Sigma, St. Louis, MO, USA), 50 μg/ml streptomycin, and
100 U/ml penicillin in 75 cm2 plastic flasks (Nunc, Roskilde, Den-
mark), at 37°C, in a humid incubator with 5% CO2/95% air. The
cell line was passaged once a week. The cells for the experiment
were obtained from passages 3-7 and inoculated in 24-well plates
(Nunc, Roskilde, Denmark) at 5 × 104 cells/well and grown to 85%
confluence in Dulbecco's modified Eagle's medium (DME/F12,
Sigma, St. Louis, MO, USA) supplemented as above. During the
experiments, cells were detached with 0.05% trypsin/0.02% EDTA
(Sigma, St. Louis, MO, USA).
Experiments were conducted in plates in DME/F12 Ham
(Sigma, St. Louis, MO, USA), supplemented with a synthetic sub-
stitute of CPSR-1 serum (Sigma, St. Louis, MO, USA). Incubation
of the MCF-7 cells with the examined substances was performed
for 24 hours.
[3H]thymidine incorporation. Cell proliferation in the culture
was assessed based on  incorporation of [3H]thymidine (Amer-
sham, United Kingdom, specific activity 925 GBq/mmol), after
incubation of the cell culture in the medium with or without the
examined substances. Two hours prior to the termination of the
experiment, [3H] thymidine was added to the culture at 18.8
KBq/well. After 2 - 3 washings of the culture with cold phosphate
buffer, tripsinisation and precipitation (3 washings with 10%
trichloroacetic acid), the precipitate was flooded with Instagel
scintillation fluid (Packard, Groningen, The Netherlands).
Radioactivity  was expressed in dpm per well.
Immunocytochemical examinations. Immunocytochemical
examinations were carried out in chambers for histochemical
examinations (Lab-tek 4 well chamber slide, Nunc, Naperville, IL,
USA). Cell material was fixed with cytofix (Cytofix, Merck,
Darmstadt, Germany). A 2-step streptavidin-biotin LSAB kit +
HRP kit (with horse-radish peroxidase) was used for detection. The
antigen-antibody reaction was visualized with the chromogen
DAB (diaminobenzidine). The cells were counted with the use of
Olympus MicroImage ImCD UDF morphometric program. The
individual microscopic fields were photographed and then the cells
were counted on the monitor and the percentage of immunoposi-
tive cells in comparison to all cells was established.
Statistical analysis. In all the experiments, mean values ± standard
deviation (SD) for 4 measurements of each parameter were calcu-
lated. The Mann-Whitney test was used to perform statistical
analysis.
Results
In our study the incorporation of [3H]thymidine into
cancer cells was inhibited by 0.2, 0.5 and 1 μM of doc-
etaxel to 50% in the 24-hour culture. No stimulating
effect of estradiol (0.001 μM) in the culture medium
with such concentrations of chemotherapeutic agent
was observed. The percentage of proliferating cells
was 52.78, 66.45 and 53.61% respectively. However,
in combination with tamoxifen we observed a statisti-
cally significant decrease of the percentage of the pro-
liferating cells in the culture medium with 0.2 and 0.5
μM of docetaxel (38.99±2.84%, p<0.01 and
40.67±5.62%, p<0.01 compared to the docetaxel
group) (Fig. 1). Such a result was also confirmed by
immunocytochemical investigations.            
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Fig. 1. The influence of docetaxel and docetaxel combined with
estradiol or tamoxifen on [3H] thymidine incorporation (in %) into
MCF-7 breast cancer cells. Legend: z - docetaxel,  - docetaxel +
estradiol 0.001 µM, S - docetaxel + tamoxifen 10 µM. Exposure
time 24 hrs. Control = 100 %. Data presented as mean values ±  SD
(n = 4). (Estradiol = 152.37 ± 10.22%, tamoxifen = 56.17 ±
2.23%). z - p < 0.01 relative to the docetaxel group 0.2 µM, S - p
< 0.01 relative to the docetaxel group 0.5 µM
All-trans retinol, β-carotene and lycopene were
used in concentration of 0.1 μM and retinoids in con-
centration of 10 μM in experiments with the exposi-
tion of MCF-7 cells lines on retinol, carotenoids and
retinoids.  
Only, 13-cis retinoic acid inhibited cancer cells
growth in 54% during 24 hrs incubation  (Table 1).
Among the examined vitamin A family compounds β-
carotene (0.1 μM) combined with docetaxel (0.2 μM)
resulted in a statistically significant reduction in the
percentage of proliferating cells (40.25 ± 14.62%,
p<0.01). Lycopene (0.1 μM), which stimulated the
growth of breast cancer cells in a 24-hour culture
(Table 1), inhibited the growth of cancer cells
(42.97±9.58%, p<0.01) when combined with docetax-
el (0.2 μM) (Table 2).
The percentage of the cells demonstrating expres-
sion of PCNA and Ki 67 is presented in Table 3.
We observed the statistically significant values in
the culture medium with docetaxel and 13-cis retinoic
acid (Ki 67),  and with docetaxel and all-trans retinoic
acid (PCNA) compared to the docetaxel group 0.2 μM.
They were also statistically significant values com-
pared to the values in 13-cis retinoic acid and all-trans
retinoic acid group (unpublished data).
Discussion
Docetaxel is one of the most active anticancer agents
in the treatment of breast cancer. The mechanism of
docetaxel activity include  the influence on cell cycle
regulation. Recent studies indicates that this activity
of taxanes originate in part from induction of genes
encoding enzymes which take part in proliferation
and other anti-proliferative factors [17]. In our study
we have shown, that its activity in MCF-7 breast can-
cer cell line was most effective in the 24-houres
exposure of concentration of 0.2, 0.5 and 1 μM. Hill
et al. [18] confirmed that 24-houres exposure of var-
ious tumor cells on increasing concentrations of doc-
etaxel resulted in a plateau-shaped curve (IC50 ranged
from 0.13 to 3.3 ng/ml). In our study a docetaxel
dose-response curve shows that the growth of MCF-
7 was inhibited by docetaxel with or without estradi-
ol supplementation. The information about docetaxel
activity in presence of estrogens is limited. Estrogens
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Table 1. The influence of all-trans retinol. carotenoids and retinoids on [3H] thymidine incorporation into MCF-7 breast cancer cells.
Exposure time 24 hrs. Control = 100%. Data (% control) presented as mean values ± SD (n=4).
Table 2. The influence all-trans retinol, carotenoids and retinoids combined with docetaxel and docetaxel with estradiol or docetaxel with
tamoxifen on [3H] thymidine incorporation into MCF-7 breast cancer cells. Exposure time 24 hrs. Control = 100 %. Data (% control) pre-
sented as mean values ± SD (n=4). * - p<0.01 relative to the docetaxel group 0.2 µM
are important regulators of growth and differentiation
in normal mammary gland and are important factors
in development and progression of breast cancer [19].
Estradiol regulates the expression of estrogen respon-
sive genes involved in regulation of cell growth, pro-
liferation and differentiation and this regulation is
mediated by estrogen receptors (ERα and ERβ) [20].
Brown et al. [21] demonstrated that 50% inhibitory
concentration for docetaxel in ER+ (MCF-7) was 15
nmol/l versus 40 nmol/l in ER- (MDA-MB-231)
cells. The results presented by Mueck et al. [22], con-
cerning the influence of  endogenous estradiol
metabolite - 2-Methoxyestradiolu (2ME) in combina-
tion with docetaxel on MCF-7 breast cancer cells,
demonstrated an additive effect. On the other hand,
Kim et al. [23] revealed that estrogen administration
decreased sensitivity both in ER+ and ER- breast
cancer cells to anticancer drugs, for example, tax-
anes. The latest data revealed  that 17-β estradiol sig-
nificantly reduces cytotoxicity of taxanes (paclitaxel)
in ERα+ breast cancer cells but has no influence on
ERα- cells [24].
Ferlini et al. [25] observed that docetaxel in combi-
nation with tamoxifen more effectively inhibited the
growth of ER- breast cancer cells than single agent.
They observed the synergism when docetaxel was
used at 0.2 and tamoxifen at 1 μM. To investigate the
possible interaction between docetaxel and tamoxifen
we used ER+ breast cancer cells. In our study tamox-
ifen significantly enhanced inhibitory effect of 0.2 and
0.5 μM docetaxel. 
In vitro experiments demonstrated that compounds
belonging into vitamin A family were able to inhibit
growth of many cells lines and the effect was most
pronounced in estrogen receptors positive cells (ER+)
[26]. Lu et al. [27] indicated that  there is a gene acti-
vation pathway in which ERα drives retinoic acid
receptor α (RARα) transcription and RARα drives
cellular retinoic acid binding protein II (CRABP II)
transcription in MCF-7 cells. β-carotene and lycopene
inhibited the growth of MCF-7 cells but in prolonged
time of incubation (up to 9 days) [12]. Hirsch et al.
[28] confirmed that these compounds inhibit estrogen
signaling of 17β-estradiol in MCF-7 breast cancer
cells. Although β-carotene and lycopene belong to the
different chemical groups, they surprisingly inhibit the
growth and proliferation of MCF-7 breast cancer cells
in combination with docetaxel in 24-hours culture. 
Retinoic acid, a major metabolite of vitamin A,
inhibits growth and differentiation of many cancer cell
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Table 3. The influence of the studied compounds and their combi-
nations on the percentage of PCNA- and Ki67-positive MCF-7
breast cancer cells. Exposure time 24 hrs. Data presented as mean
values ± SD (n=4). Statistically significant differences relative to
the control group, ns - statistically not significant.
Table 4. The influence of the all-trans retinol, caretonoids and
retinoids combined with docetaxel on the percentage of PCNA-
and Ki67-positive MCF-7 breast cancer cells. Exposure time 24
hrs. Data presented as mean values ± SD (n = 4).
Statistically significant differences relative to the control group,
ns - statistically not significant, * - p<0.01, ** - p<0.001 - statistically sig-
nificant differences relative to the docetaxel 0.2 µM group.
lines in vitro as well as inhibits cancer growth in vivo.
In in vitro conditions, retinoids prevent or diminish the
development of induced carcinogenesis in breast cells
[29]. Budman and Calabro [10] observed that 9-cis
retinoic acid synergized with docetaxel in MCF-7 cell
line. Also all-trans retinoic acid act in this way [16]. In
our study we didn't observe above-mentioned effect
and didn't demonstrated significant influence of
retinoids on response of MCF-7 cells to docetaxel. All-
trans retinoic acid when combined with docetaxel
decreased the percentage of proliferating cells but not
in statistically significant way.
The examination of cells proliferation rate is very
important prognostic and predictive factor in breast
cancer. In our study, we didn't observe significant
decrease of Ki 67 positive cells in comparison to
PCNA positive cells when cells line were exposed to
different concentrations of docetaxel. PCNA is essen-
tial component of the DNA replication events, so this
gradually decrease means, that DNA replication
lessen and result in slower cell proliferation. The per-
centage of Ki 67 and PCNA positive cells was com-
parable in cells line exposed to docetaxel in combi-
nation with either estradiol or tamoxifen. Both PCNA
and Ki 67 are present in S, G1 and G2/M phase of the
cell cycle [30,31]. The breast cancer cells are most
sensitive to docetaxel in G2/M phase [32]. The high-
est percentage of Ki 67 and PCNA positive cells was
observed in culture with 1 μM of docetaxel and 0.001
μM of estradiol. This results need some further inves-
tigations.
In vivo studies didn't  demonstrated any correlation
between percentage of Ki 67 positive cells and the
response to docetaxel [32,33].  But Ki 67 is frequently
evaluated after the neoadjuvant chemotherapy. Lee
and coworkers [34] confirmed that most of the pos-
treatment ER+ breast tumors were negative for biolog-
ical marker Ki 67. Therefore, Ki 67 proliferation index
and ER status may be used as prognostic factors for a
prediction of survival following neoadjuvant
chemotherapy in breast cancer.
Our results confirmed that there is a hormonal con-
trol of growth and proliferation in the MCF-7 cells
during exposition on docetaxel. We also found that
there is dissociation between influence of carotenoids
and retinoids on response of breast cancer cells to doc-
etaxel. The application of docetaxel either with 
β-carotene or lycopene had comparable inhibitory
effect on breast cells growth and proliferation as
tamoxifen. Therefore, it may suggest a possible impor-
tant role of these carotenoids in the breast cancer ther-
apy in women especially when docetaxel is applied.
There is evidence that β-carotene can bind the retinoid
receptors without being cleaved to form vitamin A [35]
so maybe this process is enhanced by docetaxel in
MCF-7 cells.
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